Preterm Delivery Risk With Subchorionic Hemorrhage and Normal Midtrimester Cervical Length
At 21 weeks’ gestation, a cervical length of 44–47 mm is not a “short cervix” threshold used to guide preterm birth prevention with vaginal progesterone in singleton pregnancies without prior spontaneous preterm birth. [1] Subchorionic hematoma has not been consistently associated with increased preterm delivery risk when data are focused on first-trimester SCH. [2] A precise individualized risk of preterm delivery cannot be estimated from SCH size, prophylactic enoxaparin, aspirin use, and the listed testing results alone in the available evidence. [1], [2]
Risk Estimates From Available Evidence
A meta-analysis of singleton pregnancies reported that first-trimester subchorionic hematoma was not significantly associated with preterm delivery (odds ratio 1.11, 95% CI 0.82–1.51). [2] The evidence base most strongly quantifies risk for first-trimester SCH rather than isolated midtrimester (e.g., ~21 weeks) small SCH, so direct translation to the current gestational age is limited. [2]
Cervical Length–Based Assessment and Prevention Interventions
Vaginal progesterone is recommended for singleton pregnancies without a history of spontaneous preterm birth when transvaginal cervical length is ≤20 mm before 24 weeks’ gestation. [1] Vaginal progesterone may be considered at a transvaginal cervical length of 21–25 mm based on shared decision-making. [1] A cervical length of 44–47 mm is above the 25 mm threshold used for progesterone consideration in the SMFM short-cervix framework. [1] Cerclage is not recommended for prevention of preterm birth in individuals without a history of preterm birth who have sonographic short cervix (10–25 mm) in the absence of cervical dilation. [1]
Management of the Subchorionic Hemorrhage Finding
Expectant management with surveillance is appropriate when the pregnancy is otherwise stable and there is no cervical shortening or cervical dilation consistent with cervical insufficiency. [1] Serial transvaginal cervical length assessment is appropriate to monitor for the development of cervical shortening consistent with a short-cervix indication. [1] Repeat evaluation for preterm labor symptoms and obstetric complications should be performed based on clinical status rather than SCH alone. [1]
Anticoagulation and Low-Dose Aspirin Considerations
Prophylactic enoxaparin and low-dose aspirin do not replace guideline-based cervical-length–guided prevention strategies for spontaneous preterm birth. [1] Adjustment of anticoagulation for SCH-related management is not determined by the listed test results in the provided evidence and requires the underlying indication for anticoagulation and bleeding severity to be assessed clinically.
Treatment Initiation Thresholds Applied to This Scenario
No initiation of vaginal progesterone is indicated by the SMFM short-cervix thresholds when transvaginal cervical length is 44–47 mm at 21 weeks’ gestation in a singleton pregnancy without prior spontaneous preterm birth. [1] No cerclage placement is indicated for prevention of preterm birth in the absence of cervical dilation and without a short-cervix sonographic pattern in the recommended range. [1]
Common Pitfalls to Avoid
Progesterone therapy should not be initiated based solely on the presence of a subchorionic hemorrhage when cervical length is not in the short-cervix range. [1] Cerclage should not be placed for prevention of preterm birth in the absence of cervical dilation when cervical length is not in the short-cervix range. [1]
Goals of Ongoing Obstetric Surveillance
The management goal is prevention of spontaneous preterm birth by identifying cervical shortening early with standardized transvaginal cervical length measurement. [1] The secondary goal is early detection of preterm labor or obstetric deterioration requiring escalation of care. [1]